Tunable antibodies

Nature Biotechnology

Volumn 23, Issue 5, 2005, Pages 556-557

  Weiner, Louis M ^a   Carter, Paul ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; TUMORS;

ADCC; BINDING AFFINITY; TUNABLE ANTIBODIES;

ANTIBODIES;

CD20 ANTIGEN; CETUXIMAB; FC RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; BINDING SITE; CANCER; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN ENGINEERING; SHORT SURVEY; SITE DIRECTED MUTAGENESIS; TARGET CELL; ANTIBODY PRODUCTION; ARTICLE; BIOSYNTHESIS; GENETICS; METHODOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; DRUG DESIGN; PROTEIN ENGINEERING;

EID: 22844440336     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0505-556     Document Type: Short Survey

References (9)

1. Keystone Symposium: Antibody-based Therapeutics for Cancer, Hilton Hotel, Santa Fe, New Mexico, February 17-22, 2005.
2. Schier, R. et al. J. Mol. Biol. 263, 551-567 (1996).
3. Colby, D.W. et al. Methods Enzymol. 388, 348-358 (2004).
4. Weaver-Feldhaus, J.M. FEBS Lett. 564, 24-34 (2004).
5. Weinstein, J.N. et al. Ann. NY Acad. Sci. 507, 199-210 (1987).
6. Adams G.P. et al. Cancer Res. 61, 4750-4755 (2001).
7. Graft, C.P. et al. Protein Eng. Des. Sel. 17, 293-304 (2004).
8. Cartron, G. et al. Blood 99, 754-758 (2002).
9. Weng, W.K. & Levy, R. J. Clin. Oncol. 21, 3940-3947 (2001).